| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444480 | European Journal of Cancer | 2013 | 7 Pages |
Abstract
The median OS in patients treated with targeted therapies for mRCC in The Institut Gustave Roussy exceeds 2Â years. The use of second line varies from 52% to 79%. Further studies are needed to validate the MSKCC groups and first line therapy as predictive factor for second line treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Antonin Levy, Jean Menard, Laurence Albiges, Yohann Loriot, Mario Di Palma, Karim Fizazi, Bernard Escudier,